$CLPT
ClearPoint Neuro, Inc. Stock $clpt

$clpt Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000128555023000046 Filed on May 11, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$5.950M	$5.433M
YoY Change	14.42%	7.99%
Cost Of Revenue	$2.824M	$2.231M
YoY Change	45.34%	24.99%
Gross Profit	$3.126M	$3.202M
YoY Change	-4.02%	-1.36%
Gross Profit Margin	52.54%	58.94%
Selling, General & Admin	$3.178M	$2.958M
YoY Change	-38.61%	8.27%
% of Gross Profit	101.66%	92.38%
Research & Development	$3.605M	$3.023M
YoY Change	57.84%	19.34%
% of Gross Profit	115.32%	94.41%
Depreciation & Amortization	$156.0K	$129.0K
YoY Change	54.46%	50.0%
% of Gross Profit	4.99%	4.03%
Operating Expenses	$6.783M	$5.981M
YoY Change	-9.09%	13.6%
Operating Profit	-$7.131M	-$5.712M
YoY Change	69.62%	47.83%
Interest Expense	$81.00K	$114.0K
YoY Change	-189.01%	7.55%
% of Operating Profit
Other Income/Expense, Net	-$2.000K	-$11.00K
YoY Change	-75.0%	-200.0%
Pretax Income	-$7.052M	-$5.609M
YoY Change	63.89%	41.68%
Income Tax
% Of Pretax Income
Net Earnings	-$7.052M	-$5.609M
YoY Change	63.89%	41.68%
Net Earnings / Revenue	-118.52%	-103.24%
Basic Earnings Per Share	-$0.29	-$0.23
Diluted Earnings Per Share	-$0.29	-$0.23
COMMON SHARES
Basic Shares Outstanding	24.58M shares	24.61M shares
Diluted Shares Outstanding	24.58M shares	24.58M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.46M	$31.74M
YoY Change	-41.37%	-36.09%
Cash & Equivalents	$26.50M	$21.80M
Short-Term Investments	$0.00	$9.943M
Other Short-Term Assets	$2.244M	$1.764M
YoY Change	47.92%	364.21%
Inventory	$9.204M	$9.808M
Prepaid Expenses
Receivables	$2.799M	$2.678M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$40.71M	$45.99M
YoY Change	-28.12%	-20.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.360M	$949.0K
YoY Change	-49.27%	33.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$156.0K	$131.0K
YoY Change	-73.91%	39.36%
Total Long-Term Assets	$6.930M	$4.262M
YoY Change	92.55%	13.5%
TOTAL ASSETS
Total Short-Term Assets	$40.71M	$45.99M
Total Long-Term Assets	$6.930M	$4.262M
Total Assets	$47.64M	$50.25M
YoY Change	-20.91%	-18.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.273M	$1.352M
YoY Change	-20.04%	40.1%
Accrued Expenses	$4.205M	$3.421M
YoY Change	30.75%	38.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.202M	$6.054M
YoY Change	13.11%	52.38%
LONG-TERM LIABILITIES
Long-Term Debt	$9.921M	$9.907M
YoY Change	0.57%	0.57%
Other Long-Term Liabilities	$4.108M	$1.706M
YoY Change	98.26%	-22.94%
Total Long-Term Liabilities	$14.03M	$11.61M
YoY Change	17.53%	-3.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.202M	$6.054M
Total Long-Term Liabilities	$14.03M	$11.61M
Total Liabilities	$20.23M	$17.67M
YoY Change	16.14%	10.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$163.0M	-$156.0M
YoY Change		13.13%
Common Stock	$190.4M	$188.6M
YoY Change		2.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.41M	$32.58M
YoY Change
Total Liabilities & Shareholders Equity	$47.64M	$50.25M
YoY Change	-20.91%	-18.65%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$7.052M	-$5.609M
YoY Change	63.89%	41.68%
Depreciation, Depletion And Amortization	$156.0K	$129.0K
YoY Change	54.46%	50.0%
Cash From Operating Activities	-$5.075M	-$5.700M
YoY Change	1.89%	32.56%
INVESTING ACTIVITIES
Capital Expenditures	$490.0K	$138.0K
YoY Change	-744.74%	100.0%
Acquisitions
YoY Change
Other Investing Activities	$10.00M
YoY Change	-146.32%
Cash From Investing Activities	$9.510M	-$138.0K
YoY Change	-143.89%	-25.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	237.0K	-$5.000K
YoY Change	-53.8%	-266.67%
NET CHANGE
Cash From Operating Activities	-5.075M	-$5.700M
Cash From Investing Activities	9.510M	-$138.0K
Cash From Financing Activities	237.0K	-$5.000K
Net Change In Cash	4.672M	-$5.823M
YoY Change	-117.88%	30.82%
FREE CASH FLOW
Cash From Operating Activities	-$5.075M	-$5.700M
Capital Expenditures	$490.0K	$138.0K
Free Cash Flow	-$5.565M	-$5.838M
YoY Change	13.46%	33.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001285550
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-34822
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ClearPoint Neuro, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	58-2394628
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	120 S. Sierra Ave.
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Solana Beach
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92075
CY2023Q1	dei	City Area Code CityAreaCode	(888)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	287-9109
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	CLPT
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24582251	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21792000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27615000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	9943000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	9874000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2678000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2665000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	9808000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9303000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1764000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1723000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	45985000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	51180000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	949000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	806000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1762000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1895000	usd
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	450000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	450000	usd
CY2023Q1	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	970000	usd
CY2022Q4	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	1028000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	131000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	131000	usd
CY2023Q1	us-gaap	Assets Assets	50247000	usd
CY2022Q4	us-gaap	Assets Assets	55490000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1352000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	272000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1454000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2824000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1396000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2065000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	571000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	561000	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1281000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1066000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6054000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6788000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1386000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1532000	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	320000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	390000	usd
CY2023Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	9907000	usd
CY2022Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	9893000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	17667000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	18603000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24582251	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24582251	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24578983	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24578983	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	246000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	246000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	188310000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	187008000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-155976000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-150367000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	32580000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	36887000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50247000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55490000	usd
CY2023Q1	us-gaap	Revenues Revenues	5433000	usd
CY2022Q1	us-gaap	Revenues Revenues	5031000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	2231000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	1800000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	3202000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	3231000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3023000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2901000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2933000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2018000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2958000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2176000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5712000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3864000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	114000	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-106000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5609000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3959000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24583163	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24583163	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23682442	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23682442	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	36887000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1307000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	5000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5609000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	32580000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	48787000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	899000	usd
CY2022Q1	clpt	Warrant And Option Exercises Cash And Cashless WarrantAndOptionExercisesCashAndCashless	3000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3959000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	45730000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5609000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3959000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	171000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-61000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	129000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	86000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1307000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	899000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	14000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13000	usd
CY2023Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	142000	usd
CY2022Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	133000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	69000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	184000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-155000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	578000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	880000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	42000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-128000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-30000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-959000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-692000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-146000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-128000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	144000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5680000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4269000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	138000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	69000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	116000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-138000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-185000	usd
CY2023Q1	clpt	Proceeds From Stock Option And Warrant Exercises ProceedsFromStockOptionAndWarrantExercises	0	usd
CY2022Q1	clpt	Proceeds From Stock Option And Warrant Exercises ProceedsFromStockOptionAndWarrantExercises	3000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5823000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4451000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27615000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54109000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21792000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49658000	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	179000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	100000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	100000	usd
CY2023Q1	clpt	Net Transfers Of Reusable Components From Loaned Systems NetTransfersOfReusableComponentsFromLoanedSystems	100000	usd
CY2022Q1	clpt	Net Transfers Of Reusable Components From Loaned Systems NetTransfersOfReusableComponentsFromLoanedSystems	100000	usd
CY2023Q1	clpt	Number Of Companies NumberOfCompanies	50	company
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-156000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5700000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16200000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with the Company’s December 31, 2022 audited consolidated financial statements, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth therein. These condensed consolidated financial statements have been prepared in accordance with SEC rules for interim financial information, and, therefore, omit certain information and footnote disclosures necessary to present such statements in accordance with GAAP. The preparation of these condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s 2022 Form 10-K. The accompanying condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all information and footnotes required by GAAP for a complete set of financial statements. The results of operations for the three months ended March 31, 2023, may not be indicative of the results to be expected for the entire year or any future periods.</span></div>
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration Risks and Other Risks and Uncertainties</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company may at times invest its excess cash in interest bearing accounts and U.S. government debt securities. It classifies all highly liquid investments with original stated maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months but less than twelve months as short-term investments. The Company classifies the U.S. government debt securities as held-to-maturity in accordance with ASC 320, "Investments - Debt and Equity Securities." Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity and are recorded at amortized cost on the accompanying condensed consolidated balance sheet, adjusted for the accretion of discounts using the effective interest method.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds the remainder of its cash and cash equivalents on deposit with financial institutions in the U.S. insured by the Federal Deposit Insurance Corporation. At March 31, 2023, the Company had approximately $1.7 million in bank balances that were in excess of the insured limits. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023, there was one customer whose accounts receivable balance represented 23% of accounts receivable at that date and two customers who each represented 10% of the balance. At December 31, 2022, one customer accounted for 19% of accounts receivable at that date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One pharmaceutical customer, a related party who is a stockholder, a noteholder, and who has a representative on the Company's Board of Directors (see Note 6), for whom the Company provides hardware, software, clinical services and market development services in support of the customer's clinical trials, and from whom the Company earns a quarterly fee, accounted for 13% and 19% of total sales in the three-month periods ended March 31, 2023 and 2022, respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to granting credit to a customer, the Company performs credit evaluations of the customers’ financial condition. In general, the Company does not require collateral from customers in connection with an extension of credit. The accounts receivable balance is reduced by an allowance for credit losses from the potential inability of the Company's customers to make required payments. The allowance for credit losses at March 31, 2023, and December 31, 2022, was $0.3 million and $0.1 million, respectively. The Company evaluates the historic loss experience on the accounts receivable balance and also considers separately customers with receivable balances that may be negatively impacted by current economic developments and market conditions. The estimate is a result of the Company's ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; dependence on third-party collaboration, license and joint development partners; changes in general economic conditions and interest rates; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company’s supply requirements may negatively impact future operating results.</span></div>
CY2023Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1700000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	usd
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated statement of operations for the three months ended March 31, 2023 classifies share-based compensation in the same income statement line items as the cash compensation paid to recipient employees, rather than in general and administrative expense, as had been the practice in previous years. The accompanying condensed consolidated statements of operations for the three months ended March 31, 2022 have been conformed to the 2023 presentation.</span></div>
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5433000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5031000	usd
CY2023Q1	clpt	Deferred Contract Costs DeferredContractCosts	400000	usd
CY2022Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	500000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21800000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27600000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	9900000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	9900000	usd
CY2023Q1	us-gaap	Inventory Gross InventoryGross	10258000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	9753000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	7308000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6513000	usd
CY2023Q1	clpt	Inventory Software Licenses InventorySoftwareLicenses	210000	usd
CY2022Q4	clpt	Inventory Software Licenses InventorySoftwareLicenses	210000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2290000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2580000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	9808000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9303000	usd
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	450000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	450000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	10000000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	93000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	9907000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	300000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	100000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1307000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	899000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1307000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	899000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1398286	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.69
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	111107	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.10
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1509393	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.65
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M1D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5336000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1134204	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.12
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M23D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5087000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1509393	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.65
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y2M1D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	5336000	usd

Files In Submission

Name	View Source	Status
clpt-20230331_def.xml	Edgar Link	unprocessable
clpt-20230331_cal.xml	Edgar Link	unprocessable
0001285550-23-000046-index-headers.html	Edgar Link	pending
0001285550-23-000046-index.html	Edgar Link	pending
0001285550-23-000046.txt	Edgar Link	pending
0001285550-23-000046-xbrl.zip	Edgar Link	pending
clpt-20230331.htm	Edgar Link	pending
clpt-20230331.xsd	Edgar Link	pending
clpt-20230331xex311.htm	Edgar Link	pending
clpt-20230331xex312.htm	Edgar Link	pending
clpt-20230331xex32.htm	Edgar Link	pending
clpt_-xamendmentxnox1xto.htm	Edgar Link	pending
clpt_-xamendmentxnox1xto001.jpg	Edgar Link	pending
clpt_-xamendmentxnox1xto002.jpg	Edgar Link	pending
clpt_-xamendmentxnox1xto003.jpg	Edgar Link	pending
clpt_-xamendmentxnox1xto004.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
jstigallemploymentagreem.htm	Edgar Link	pending
jstigallemploymentagreem001.jpg	Edgar Link	pending
jstigallemploymentagreem002.jpg	Edgar Link	pending
jstigallemploymentagreem003.jpg	Edgar Link	pending
jstigallemploymentagreem004.jpg	Edgar Link	pending
jstigallemploymentagreem005.jpg	Edgar Link	pending
jstigallemploymentagreem006.jpg	Edgar Link	pending
jstigallemploymentagreem007.jpg	Edgar Link	pending
jstigallemploymentagreem008.jpg	Edgar Link	pending
jstigallemploymentagreem009.jpg	Edgar Link	pending
jstigallemploymentagreem010.jpg	Edgar Link	pending
jstigallemploymentagreem011.jpg	Edgar Link	pending
jstigallemploymentagreem012.jpg	Edgar Link	pending
jstigallemploymentagreem013.jpg	Edgar Link	pending
jstigallemploymentagreem014.jpg	Edgar Link	pending
jstigallemploymentagreem015.jpg	Edgar Link	pending
jstigallemploymentagreem016.jpg	Edgar Link	pending
jstigallemploymentagreem017.jpg	Edgar Link	pending
jstigallemploymentagreem018.jpg	Edgar Link	pending
jstigallemploymentagreem019.jpg	Edgar Link	pending
jstigallemploymentagreem020.jpg	Edgar Link	pending
jstigallemploymentagreem021.jpg	Edgar Link	pending
clpt-20230331_lab.xml	Edgar Link	unprocessable
clpt-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
clpt-20230331_htm.xml	Edgar Link	completed
jstigallemploymentagreem022.jpg	Edgar Link	pending
jstigallemploymentagreem023.jpg	Edgar Link	pending
jstigallemploymentagreem024.jpg	Edgar Link	pending
jstigallemploymentagreem025.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLPT
ClearPoint Neuro, Inc. Stock $clpt

2023 Q2 Form 10-Q Financial Statement

#000128555023000046 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLPT ClearPoint Neuro, Inc. Stock $clpt

2023 Q2 Form 10-Q Financial Statement

#000128555023000046 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLPT
ClearPoint Neuro, Inc. Stock $clpt